0 (0%)		11-20 03:56
Open: High: Volume: 0		Pre. Close: Low: Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	105.5	1-year :	105.79
Resists	First :	90.33	Second :	90.57
Pivot price	0
Supports	First :	89.93	Second :	74.82
MAs	MA(5) :	90.39	MA(20) :	0
	MA(100) :	0	MA(250) :	0
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	0	D(3) :	0
RSI	RSI(14): 0
52-week	High :	90.57	Low :	89.94

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ATTR ] has closed Bollinger Bands are 0% narrower than normal.

If tomorrow:	Open lower	Open higher
High:	90.49 - 91.04	91.04 - 91.44
Low:	88.71 - 89.44	89.44 - 89.99
Close:	89.07 - 90.15	90.15 - 90.95

Wed, 19 Nov 2025
Clinical Burden and Barriers to Early Diagnosis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - HCPLive

Wed, 19 Nov 2025
Extra-Cardiac Clues and Care Team Integration for Earlier ATTR-CM Detection - HCPLive

Tue, 18 Nov 2025
Evercore Downgrades Intellia (NTLA) Despite Strong ATTR Trial Data - Yahoo Finance

Mon, 17 Nov 2025
5 of the Top Support Organizations for ATTR-CM - Everyday Health

Tue, 11 Nov 2025
Novo Nordisk shares mixed data behind pivotal heart disease push - Fierce Biotech

Mon, 10 Nov 2025
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy - Intellia Therapeutics

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange:
Sector:
Industry:
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.